UNSPSC 51312809: Alimemazine tartrate

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula 2C18H22N2S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362NW1LD6Z, chemically known as 10h-phenothiazine-10-propanamine n,n,beta-trimethyl-, (r-(r*,r*))-2,3-dihydroxybutanedioate (2:1) but more generally known as alimemazine tartrate, which bears US NIH Compound Identifier 78032. The base compound, Alimemazine, also comes in base and s-dioxide forms.

European Medicines Agency schedules Alimemazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00343MIG. Most nations, for tariff and trade purposes, schedule alimemazine tartrate under HS 29343000. SMILES: CC(CN1C2CCCCC2SC3C1CCCC3)CN(C)C.CC(CN1C2CCCCC2SC3C1CCCC3)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51312809 Alimemazine tartrate is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though the recent solicitations tagged under this code show activity in broader generic pharmaceuticals, over-the-counter products, and opioid-reversal agents rather than alimemazine specifically. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances that serve multiple jurisdictions. The work being solicited spans direct procurement of generic multi-source pharmaceuticals, OTC products, naloxone and drug deactivation systems for community health programs, and exploratory contracting for direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies are typically state health agencies, regional cooperative purchasing vehicles, and county public health departments seeking to manage pharmaceutical costs and supply chains for population health initiatives, emergency response, and substance-use disorder interventions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, through electronic bidding with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, asking for information on direct contracting capacity and outcomes-based agreements as a precursor to formal RFP development. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act certification, with contract award effective July 1, 2026 and spanning two years.